In vitro study of sirolimus release from a drug-eluting stent: Comparison of the release profiles obtained using different test setups

2015 ◽  
Vol 93 ◽  
pp. 328-338 ◽  
Author(s):  
Anne Seidlitz ◽  
Wiebke Schick ◽  
Thomas Reske ◽  
Volkmar Senz ◽  
Niels Grabow ◽  
...  
2012 ◽  
Vol 22 (4) ◽  
pp. 295-302 ◽  
Author(s):  
Huijuan Bian ◽  
Shaoxiong Zhou ◽  
Xinjie Liang ◽  
Qiang Li ◽  
Wei Han

2020 ◽  
Vol 21 (4) ◽  
pp. 1530
Author(s):  
Ling-Yi Cheng ◽  
Yu-Chi Wang ◽  
Ming-Hong Chen ◽  
Fu-I Tung ◽  
Kuan-Ming Chiu ◽  
...  

In-stent restenosis is a serious concern for patients treated through the stenting procedure, although this can be solved using drug-eluting stents and/or drug-eluting balloon catheters. However, the chemical agents released from the drug-eluting layer for inhibiting smooth muscle cell (SMC) migration are inevitably associated with damage to vascular endothelial cell (ECs). The present in vitro study used a distinct strategy, in which a smart gene (phEGR1-PKCδ, an engineered plasmid consists of an SMC-specific promoter (human early growth response 1, hEGR1 promoter) ligated with a gene encoding apoptosis-inducing protein (protein kinase C-delta, PKCδ) was incorporated into a novel gene vehicle (Au cluster-incorporated polyethylenimine/carboxymethyl hexanoyl chitosan, PEI-Au/CHC) to form the PEI-Au/CHC/phEGR1-PKCδ complex, which was proposed for the selective inhibition of SMC proliferation. It was found that the cell viability of SMCs receiving the PEI-Au/CHC/phEGR1-PKCδ complex under simulated inflammation conditions was significantly lower than that of the ECs receiving the same treatment. In addition, the PEI-Au/CHC/phEGR1-PKCδ complex did not demonstrate an inhibitory effect on EC proliferation and migration under simulated inflammation conditions. Finally, the PEI-Au/CHC/phEGR1-PKCδ complexes coated onto a balloon catheter used in percutaneous transluminal coronary angioplasty (PTCA) could be transferred to both the ECs and the SMC layer of Sprague Dawley (SD) rat aortas ex vivo. These preliminary in vitro results suggest that the newly developed approach proposed in the present study might be a potential treatment for reducing the incidence rate of in-stent restenosis and late thrombosis in the future.


2021 ◽  
Vol 26 (1) ◽  
Author(s):  
Alper Öner ◽  
Paula Rosam ◽  
Finja Borowski ◽  
Niels Grabow ◽  
Stefan Siewert ◽  
...  

Abstract Background Percutaneous coronary interventions (PCI) of bifurcation stenoses are both complex and challenging. Stenting strategies share that the stents’ side cells must be carefully explored and appropriately prepared using balloons or stents. So far, stent manufacturers have not provided any information regarding side-branch expansion capacity of their stent platforms. Aims Given that drug-eluting stent (DES) information regarding their mechanical capacity of side-branch expansion is not available, we aimed to evaluate contemporary DES (Orsiro, BIOTRONIK AG; Xience Sierra, Abbott Vascular; Resolute Integrity, Medtronic; Promus Premier Select, Boston Scientific; Supraflex Cruz, Sahajan and Medical Technologies) by their side-branch expansion behavior using in vitro bench testing. Methods In this in vitro study, we analyzed five commercially available DES (diameter 3.0 mm), measuring their side-branch expansion following inflation of different high-pressure non-compliant (NC) balloons (balloon diameter: 2.00–4.00 mm), thereby revealing the morphological characteristics of their side-branch expansion capacities. Results We demonstrated that all tested contemporary DES platforms could withstand large single-cell deformations, up to 4.0 mm. As seen in our side-branch experiments, DES designs consisting of only two connectors between strut rings did not only result in huge cell areas, but also in larger cell diameters following side-branch expansion compared with DES designs using three or more connectors. Furthermore, the stent cell diameter attained was below the balloon diameter at normal pressure. Conclusions We recommend that the expansion capacity of side-branches should be considered in stent selection for bifurcation interventions.


2009 ◽  
Vol 5 (8) ◽  
pp. 2894-2900 ◽  
Author(s):  
J. Mikkonen ◽  
I. Uurto ◽  
T. Isotalo ◽  
A. Kotsar ◽  
T.L.J. Tammela ◽  
...  

2013 ◽  
Vol 24 (11) ◽  
pp. 2589-2600 ◽  
Author(s):  
Svea Petersen ◽  
Janine Hussner ◽  
Thomas Reske ◽  
Niels Grabow ◽  
Volkmar Senz ◽  
...  

Author(s):  
B. Wendl ◽  
H. Wiltsche ◽  
E. Lankmayr ◽  
H. Winsauer ◽  
A. Walter ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document